Cardiovascular disease (CVD) is a set of conditions that result primarily from the build-up of plaque in the blood vessels. Depending on where there is build-up, patients can have chest pain (“angina”), muscle pain with walking (“claudication”) and an increased risk of heart attack, stroke, and death. In total, CVD is estimated to affect one-half of adults in the US and is the leading cause of death across all races and ethnicities, with approximately 850,000
deaths annually.

Treatments of Interest:

  • icosapent ethyl (Vascepa®, Amarin Pharma)
  • rivaroxaban (Xarelto®, Janssen Pharmaceuticals)

For questions, contact

View the Key Stakeholders List.

Final Documents

Below you will find the final documents from the assessment review process: